Regadenoson and Adenosine

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

Also called NCT01809743

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose diagnostic
Phase
Phase 3
Enrolled
  • 100 participants (enrolled count) (from the registry)
Sponsor
Lokien van Nunen (from the registry)
Registry
  • NCT NCT01809743
Other papers using this trial's data
  • Single bolus intravenous regadenoson injection versus central venous infusion of adenosine for maximum coronary hyperaemia in fractional flow reserve measurement EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2015-12 DOI, PubMed 25136887

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Netherlands (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01809743. Randomized; no masking; primary purpose diagnostic. Start 2013-01 (registry gives no type); primary completion 2013-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Regadenoson and Adenosine
Intervention (Drug)
Regadenoson central -central
Intervention (Drug)
Regadenoson peripheral - peripheral
Intervention (Drug)
Regadenoson central - peripheral
Intervention (Drug)
Regadenoson peripheral - central
Intervention (Drug)
Adenosine
Lead sponsor
Lokien van Nunen (class: other)

Record details

Record id
cardio:ct-nct01809743
Content hash
ddfe46d6c6835c3b6c03b049c9c8e1266886d3965548873f7864bdab37f65ea9